Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sperm protein 17 (Sp17)
- Target
- Sp17
- Molecular classification
- Sperm structural protein, Cancer/testis antigen (CTA), Tumor-associated antigen, Cell-surface protein
01
Overview
Sperm protein 17 (Sp17) is a highly conserved mammalian protein originally identified on the sperm flagellar fibrous sheath, where it is implicated in sperm maturation, fertilization, and sperm-oocyte binding[1][3]. Sp17 is now recognized to be widely distributed in both germinal (reproductive) and various somatic tissues, and is overexpressed in multiple human cancers, leading to its classification as a cancer/testis antigen (CTA)[2][5]. It contains domains homologous to protein kinase A anchoring protein and calmodulin-binding sites, and participates in protein-protein interactions important for cell signaling and motility in both sperm and cancer cells[1][2]. Its aberrant expression in tumors and functional involvement in cell migration/invasion makes Sp17 a candidate diagnostic and immunotherapeutic target, though safety and specificity remain important considerations[2][4][5].
- Other names
- Sperm surface protein Sp17SPA17 (gene symbol)Sperm autoantigenic protein 17Sperm protein antigen 17
02
Mechanism of action
Inhibiting cell surface Sp17 aims to block immune escape or tumor cell migration. Vaccine strategies are in preclinical/early clinical testing to stimulate antitumor immunity via recognition of Sp17-expressing tumor cells
03
Biological functions
Sperm maturationCapacitationAcrosomal reactionInteraction with oocyte zona pellucida (sperm-oocyte binding and fertilization)Potential role in cell-cell adhesion, motility, and signal transduction (through AKAP interactions)Possible involvement in tumor cell migration, invasion, and tumorigenesis
04
Disease associations
Cancer (notably endometrial, cervical, ovarian, breast cancer, glioma, and multiple myeloma)Other (potentially in autoimmune and reproductive disorders, but cancer is the major context)
05
Safety considerations
Tissue distribution is broader than originally thought (present in some normal tissues and ciliated epithelia), raising potential concerns regarding specificity and off-target effects, especially for immunotherapeutic approachesIts functional role outside testis and tumors remains incompletely understood
06
Interacting drugs
No approved drugs currently target Sp17 directly; however, it is under investigation as a target for cancer vaccines and immunotherapy
07
Biomarkers
Sp17 expression is being studied as a biomarker for cancer prognosis, particularly in endometrial, cervical, breast, and glioma cancers; it may predict survival or define tumor subsets
Beyond the preview
Go deeper on Sperm protein 17 (Sp17).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sperm protein 17 (Sp17).